-
Innovation Ranking
NewInnovation Ranking – Almirall SA
Almirall SA (Almirall) is a specialty pharmaceutical company that researches, develops, manufactures, and commercializes proprietary medicines and licensed products. The company’s major area of focus is dermatology covering psoriasis, eczema, psoriasis, oncodermatology, onychomicosis, actinic keratosis, acne, and other skin infections. It also develops products for autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. The company also works together with small and medium-sized companies and healthcare professionals to develop medical solutions and...
-
Company Insights
Innovation and Patenting activity of Almirall SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Almirall SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewHyaluronic Acid Fillers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Hyaluronic Acid Fillers Pipeline Market Report Overview Hyaluronic Acid (HA) is a glycosaminoglycan disaccharide, which exists naturally in the body. Approximately 50% of the total HA is found in the skin. Injections of HA are used for reducing wrinkles in the face and for soft tissue augmentation. The hyaluronic acid fillers pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the...
-
Product Insights
Cutaneous Mycosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cutaneous Mycosis - Drugs In Development, 2023’, provides an overview of the Cutaneous Mycosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cutaneous Mycosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Company Insights
Almirall – Digital Transformation Strategies
Almirall 2023 Digital Transformation Strategies Report Overview Almirall is leveraging several emerging technologies to quickly discover drugs, drive sales, streamline production, expand market presence, and help patients recover quickly. Cloud, AI, and digital therapeutics are among the technologies the company is focusing on. The annual ICT spending of Almirall is estimated at $14.7 million for 2023. A major share of this spending is earmarked for software, ICT services, and hardware. Almirall is a global biopharmaceutical company specializing in dermatology. The...
-
Product Insights
Onychomycosis (Tinea Unguium) – Drugs In Development, 2023
Global Markets Direct’s, ‘Onychomycosis (Tinea Unguium) - Drugs In Development, 2023’, provides an overview of the Onychomycosis (Tinea Unguium) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Epidermolysis Bullosa – Drugs In Development, 2023
Global Markets Direct’s, ‘Epidermolysis Bullosa - Drugs In Development, 2023’, provides an overview of the Epidermolysis Bullosa pipeline landscape. The report provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Vitiligo – Drugs In Development, 2023
Global Markets Direct’s, ‘Vitiligo - Drugs In Development, 2023’, provides an overview of the Vitiligo pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vitiligo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Androgenic Alopecia – Drugs In Development, 2023
Global Markets Direct’s, ‘Androgenic Alopecia - Drugs In Development, 2023’, provides an overview of the Androgenic Alopecia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Androgenic Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...